LOS ANGELES, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Dow Inc. (“Dow” or the “Company”) (NYSE: DOW) securities between January 30, 2025 and July 23, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR DOW INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS U ...

On 10/1/25, Air Products & Chemicals will trade ex-dividend, for its quarterly dividend of $1.79, payable on 11/10/25. As a percentage of APD's recent stock price of $266.78, this dividend works out to approximately 0.67%, so look for shares of Air Products & Chemicals Inc to trade 0.67% lower — all else being equal — when APD shares open for trading on 10/1/25. 10 Stocks Going Ex-Dividend »Below is a dividend history chart for APD, showing historical dividends prior to the most recent $1.79 declared by Air ...

Core Viewpoint - A securities class action lawsuit has been filed against Dow Inc. for allegedly making false and misleading statements regarding its financial condition and ability to manage macroeconomic challenges during the specified Class Period from January 30, 2025, to July 23, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Dow securities during the Class Period, with a lead plaintiff deadline set for October 28, 2025 [1][4]. - The complaint alleges that Dow overstated its ability to mitigate macroeconomic and tariff-related headwinds, which negatively impacted its business and financial condition [3]. Group 2: Allegations Against Dow - The allegations include that Dow failed to disclose the true scope and severity of competitive and pricing pressures, softening global sales, and an oversupply of products in its markets [3]. - It is claimed that the public statements made by Dow were materially false and misleading throughout the Class Period [3]. Group 3: Legal Representation - Investors may seek to be appointed as lead plaintiff representatives through Kessler Topaz Meltzer & Check, LLP or choose to remain absent class members [4]. - The lead plaintiff will act on behalf of all class members and select counsel to represent the class in the litigation [4].

Accessibility StatementSkip Navigation CLAYTON, Mo., Sept. 26, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today that on Tuesday, October 28, 2025, at 9:00 a.m. Eastern time, Olin's senior management will review the company's third quarter 2025 financial results. Our prepared remarks will be followed by a question-and-answer period. Following the call, the webcast will remain available for replay on the company's website for one year. A telephonic replay of this conference call will be avail ...

Press release Regulated information Brussels, September 26, 2025, 17:45 CEST In line with Belgian transparency legislation (Law of May 2, 2007), Morgan Stanley recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%. Here is a summary of the notifications: Date on which the threshold was crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total September 18, 2025 0.00% 3.13% 3.13% September 22, ...

Press release Brussels, September 25, 2025 - 17h45 CEST Solvay has amended its €1.1 billion multilateral revolving credit facility and its €0.3 billion bilateral revolving credit facilities to incorporate sustainability-linked features, aligning with its For Generations roadmap and reinforcing its commitment to reducing greenhouse gas (GHG) emissions. These amendments directly link the company’s cost of borrowing to its climate ambitions, specifically the achievement of ambitious greenhouse gas (GHG) emiss ...

PresentationIt is now the time to start, so I would like to start. My name is Kobayashi from the Corporate Communications Department. I will serve as the moderator. Thank you very much for attending today's investors' meeting for the Current Priority Management Issues and Business Strategy despite your busy schedules. Today, from our President, Mito, there will be an explanation given followed by a Q&A. We plan to end this meeting at 4:00 p.m.Nobuaki MitoPresident, CEO & Representative Director And once aga ...

Business Strategy & Portfolio Upgrade - The company aims to upgrade its business portfolio with a new growth strategy, focusing on winning businesses rooted in organic synthesis technology and cultivating new growth businesses[2, 12, 14] - The company is focusing on three blockbuster candidates in the chemicals business, aiming for sales of several tens of billions of yen by 2030[16, 17] - The company aims to expand its biorationals business to 150 billion yen by FY2030, a 2X increase from 70 billion yen in FY2024[36] - The company targets a 20% market share in cutting-edge semiconductor resist[47] Financial Targets & Capital Efficiency - The company's financial targets for FY2027 include a core operating income of 200 billion yen, ROE of 8%, ROIC of 6%, and a D/E ratio of approximately 0.8X[12] - The company expects a dividend payout ratio of over 30% during the new plan period, aiming for 24 yen/share or more per year early in the future[136, 137] Structural Reforms & Resilience - Petro Rabigh is undergoing financial improvements, including a $1.5 billion loan write-off and a $702 million contribution from the sale of approximately 22.5% of PRC to Aramco[111, 113] - The company is integrating its domestic PP and LLDPE businesses into Prime Polymer, expecting cost reductions of over 8 billion yen per year[115, 119] Advanced Medical Solutions - The company is deploying a winning CDMO strategy leveraging its strengths in advanced small molecule APIs and oligonucleotide CDMO, focusing on high-purity long-chain nucleotides[55, 69] - The company aims for its Parkinson's disease therapy using iPS cells to grow into a blockbuster with 100 billion yen in sales in the 2030s[102]

Core Viewpoint - A securities class action lawsuit has been filed against Dow Inc. for allegedly making false and misleading statements regarding its financial condition and ability to manage macroeconomic challenges during the Class Period from January 30, 2025, to July 23, 2025 [1][3]. Group 1: Allegations Against Dow Inc. - The lawsuit claims that Dow overstated its ability to mitigate macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [3]. - It is alleged that the negative impacts of competitive pressures, softening global sales, and product oversupply on Dow's business were understated [3]. - The complaint asserts that Dow's public statements were materially false and misleading throughout the Class Period [3]. Group 2: Legal Process and Participation - Investors in Dow have until October 28, 2025, to seek appointment as lead plaintiff or remain absent class members [4]. - The lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [4]. - Participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [4].

Company Overview - LyondellBasell Industries N.V. is a chemical company with a global presence, operating across six business segments including Olefins and Polyolefins [1] Business Segments - The company has a diverse product lineup that spans the plastics and petrochemical value chain, indicating a comprehensive approach to the chemical industry [1] Investment Insights - The company is positioned to identify long-term investment opportunities, particularly in sectors that offer safe and growing dividends, which may appeal to risk-adjusted return investors [1]